High-sensitivity sequencing to detect BTK inhibitor resistance

1. A method for screening and/or monitoring a patient for a BTK inhibitor-resistant mutation, the method comprising:

isolating DNA from a sample selected from bone marrow aspirate (BM), fresh peripheral blood (PB), and tissue obtained from the patient;

performing PCR on the isolated DNA to produce amplified DNA while blocking amplification of wild-type DNA in a portion of the isolated DNA that encodes a BTK polypeptide and a portion of the isolated DNA that encodes a PLCγ2 polypeptide, wherein amplification is blocked using two or more locked nucleic acids (LNA) or bridged nucleic acids (BNA) selected from SEQ ID NO. 3, SEQ ID NO. 6, SEQ ID NO. 9, and SEQ ID NO. 12;

sequencing the amplified DNA in an automated sequencer; and

analyzing an output of the automated sequencer to identify mutations in the sequence.

2. The method of claim 1 , wherein the portion of the isolated DNA that encodes a BTK polypeptide includes BTK exon 15.

3. The method of claim 1 , wherein the portion of the isolated DNA that encodes a PLCγ2 polypeptide includes one or more of PLCγ2 exon 19, 20 and 24.

4. The method of claim 1 , wherein the step of sequencing is performed using a sequencing method selected from the group consisting of Sanger sequencing, next generation sequencing, polymerase chain reaction, pyrosequencing, dye sequencing, sequencing by synthesis, and ion semiconductor sequencing.

5. The method of claim 1 , wherein the sample comprises peripheral blood plasma.

6. A kit for screening, monitoring and managing a patient with a progressive B-Cell malignancy, the kit comprising two or more LNA or BNA oligonucleotides selected from SEQ ID NO. 3, SEQ ID NO. 6, SEQ ID NO. 9 and SEQ ID NO. 12, wherein the progressive B-Cell malignancy is selected from the group consisting of chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).

7. A method for high sensitivity testing for mutations in BTK and PLCγ2, comprising using a wild-type (WT) blocking method during Sanger Sequencing on isolated DNA, wherein two or more locked nucleic acids (LNA) or bridged nucleic acids (BNA) are used to block amplification of wild-type DNA in a portion of the isolated DNA that encodes a BTK polypeptide and a portion of the isolated DNA that encodes a PLCγ2 polypeptide, wherein the two or more LNA or BNA nucleic acids are selected from SEQ ID NO. 3, SEQ ID NO. 6, SEQ ID NO. 9 and SEQ ID NO. 12.

8. The method of claim 7 , wherein the portion of the isolated DNA that encodes a BTK polypeptide includes BTK exon 15.

9. The method of claim 7 , wherein the portion of the isolated DNA that encodes a PLCγ2 polypeptide includes one or more of PLCγ2 exon 19, 20 and 24.

10. The method of claim 7 , wherein the isolated DNA is extracted from peripheral blood plasma.

11. A method for high sensitivity testing for BTK and PLCγ2 mutations comprising using a wild-type blocking method during next-generation sequencing (NGS) on isolated DNA, wherein two or more locked nucleic acids (LNA) or bridged nucleic acids (BNA) are used to block amplification of wild-type DNA in a portion of the isolated DNA that encodes a BTK polypeptide and a portion of the isolated DNA that encodes a PLCγ2 polypeptide, wherein the two or more LNA or BNA nucleic acids are selected from SEQ ID NO. 3, SEQ ID NO. 6, SEQ ID NO. 9 and SEQ ID NO. 12.

12. The method of claim 11 , wherein the portion of the isolated DNA that encodes a BTK polypeptide includes BTK exon 15.

13. The method of claim 11 , wherein the portion of the isolated DNA that encodes a PLCγ2 polypeptide includes one or more of PLCγ2 exon 19, 20 and 24.

14. The method of claim 11 , wherein the isolated DNA is extracted from peripheral blood plasma.